Results 31 to 40 of about 2,108 (191)

Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema [PDF]

Purpose: To compare anatomic biomarkers on spectral-domain OCT between faricimab, a dual angiopoietin-2 (Ang-2)/VEGF-A inhibitor, and aflibercept in a pooled analysis of results from the YOSEMITE/RHINE trials in diabetic macular edema (DME).
Amador M. J., Dhoot D. S., Finn A., Fraser-Bell S., Gibson K., Idowu O. O., Khurana R. N., Lai T. Y. Y., Lanzetta P., Lim J. I., Lin T. -C., Mar F. A., Pollreisz A., Rachitskaya A., Schlottmann P. G., Tang Y.   +15 more
core   +1 more source

Evaluating the Real-World Efficacy and Safety of Intravitreal Faricimab in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review

IJRETINA (International Journal of Retina)
Introduction: Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss in the elderly. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies have revolutionized the treatment of nAMD ...
Dany Petra Pranata Barus, Gitalisa Andayani Adriono   +1 more
doaj   +1 more source

Dual acting therapeutic proteins for intraocular use [PDF]

, 2020
Antibody-based medicines that target vascular endothelial growth factor (VEGF) are administered by intravitreal injection to treat chronic neovascular retinal diseases.
Awwad, S., Awwad, S., Brocchini, S., Brocchini, S., Collins, M., Collins, M., Guiliano, D., Guiliano, D., Ibeanu, N., Ibeanu, N., Khalili, H., Khalili, H., Khaw, P. T., Khaw, P. T.   +13 more
core   +1 more source

Risk factors and treatment strategy for retinal vascular occlusive diseases [PDF]

, 2022
Retinal occlusive diseases are common diseases that can lead to visual impairment. Retinal artery occlusion and retinal vein occlusion are included in the clinical entity, but they have quite different pathophysiologies.
Ahmed, Tazbir, Fujino, Ryosuke, Terao, Ryo   +2 more
core   +2 more sources

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies, Yohei Hashimoto, Rahman Nazari, Jennifer Arnold, Beibei Wang, Richard Barry, Ross Ferrier, Justin Game, Daniel Barthelmes   +8 more
wiley   +1 more source

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose [PDF]

, 2023
Background: The effects of various dosages and treatment regimens on intravitreal aflibercept concentrations and the proportion of free vascular endothelial growth factor (VEGF) to total VEGF were evaluated using a drug and disease assessment model.
Di Bin, Francesco, Lanzetta, Paolo, Sarao, Valentina, Veritti, Daniele   +3 more
core   +1 more source

BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion

Ophthalmology Science, 2023
Purpose: Dual inhibition of angiopoietin-2 and VEGF-A with faricimab (Vabysmo) offers excellent visual acuity gains with strong durability in patients with diabetic macular edema (ME) and neovascular age-related macular degeneration.
Lars-Olof Hattenbach, MD, PhD, Francis Abreu, PhD, Pablo Arrisi, PhD, Karen Basu, PhD, Carl J. Danzig, MD, Robyn Guymer, MD, PhD, Zdenka Haskova, MD, PhD, Jeffrey S. Heier, MD, Aachal Kotecha, PhD, Ying Liu, PhD, Anat Loewenstein, MD, András Seres, MD, Jeffrey R. Willis, MD, PhD, Charles C. Wykoff, MD, PhD, Liliana P. Paris, MD, PhD   +14 more
doaj   +1 more source

Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration [PDF]

Purpose: To report short-term outcomes of treatment switch to faricimab in real-world patients with aflibercept-resistant neovascular age-related macular degeneration (AMD).
Bjerager, Jakob, Hajari, Javad, Hodzic-Hadzibegovic, Delila, Klefter, Oliver Niels, Schneider, Miklos, Subhi, Yousif   +5 more
core   +1 more source

Proteolytic remodelling of the extracellular matrix by pericytes

The FEBS Journal, EarlyView.
Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard, Ella Milne, Kate Qian, Paola Campagnolo, Salvatore Santamaria   +4 more
wiley   +1 more source